Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on Kezar Life Sciences (KZR – Research Report). The associated price target is $2.00.
Derek Archila has given his Hold rating for Kezar Life Sciences due to several factors. The company’s recent CEO changes and restructuring efforts, although extending their cash runway, fail to present any clear near-term stock catalysts. Despite the ongoing clinical development of zetomipzomib, the lack of new updates and unchanged timelines fail to generate investor interest or significantly alter market sentiment in the near term.
Archila also highlights the cautious approach towards KZR-261, with its Phase 1 data expected in 2024. Despite the drug’s clean safety profile so far, the lack of reported efficacy and low probability of success contribute to a lack of market confidence in this program. Furthermore, the recent change in management does not present any clear strategic changes as of yet. Lastly, even though the company ended 3Q23 with a substantial cash reserve, the future prospects of KZR-261 and zeto’s trials, coupled with a lack of a regulatory path, make it difficult for investors to assign value.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Kezar Life Sciences (KZR) Company Description:
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Read More on KZR:
